MCRPC (METASTATIC CASTRATION-RESISTANT PROSTATE CANCER)
Clinical trials for MCRPC (METASTATIC CASTRATION-RESISTANT PROSTATE CANCER) explained in plain language.
Never miss a new study
Get alerted when new MCRPC (METASTATIC CASTRATION-RESISTANT PROSTATE CANCER) trials appear
Sign up with your email to follow new studies for MCRPC (METASTATIC CASTRATION-RESISTANT PROSTATE CANCER), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for tough prostate cancer? early trial begins
Disease control Recruiting nowThis early-stage study tests a new drug called ACE-232 in people with a hard-to-treat type of advanced prostate cancer that has stopped responding to standard therapies. The main goals are to check the drug's safety, find the right dose, and see early signs of whether it can help…
Matched conditions: MCRPC (METASTATIC CASTRATION-RESISTANT PROSTATE CANCER)
Phase: PHASE1 • Sponsor: Acerand Therapeutics (Hong Kong) Limited • Aim: Disease control
Last updated May 26, 2026 03:15 UTC
-
New drug combo targets tough prostate cancer in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called KTX2001, alone or with another drug (darolutamide), in men with advanced prostate cancer that no longer responds to standard hormone therapy. The main goals are to check safety, find the best dose, and see if it helps control the can…
Matched conditions: MCRPC (METASTATIC CASTRATION-RESISTANT PROSTATE CANCER)
Phase: PHASE1 • Sponsor: K36 Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 03:12 UTC
-
New hope for hard-to-treat prostate cancer: experimental drug combo enters human trials
Disease control Recruiting nowThis study tests a new drug called pocenbrodib, either alone or with other treatments, in people with a type of advanced prostate cancer that no longer responds to standard hormone therapy. The goal is to find the safest dose and see if it can shrink tumors or lower PSA levels. A…
Matched conditions: MCRPC (METASTATIC CASTRATION-RESISTANT PROSTATE CANCER)
Phase: PHASE1, PHASE2 • Sponsor: Pathos AI, Inc. • Aim: Disease control
Last updated May 26, 2026 03:11 UTC
-
New drug cocktail aims to stall advanced prostate cancer
Disease control Recruiting nowThis study tests a new two-drug combination (gedatolisib plus darolutamide) in men with metastatic castration-resistant prostate cancer (mCRPC) — a form of prostate cancer that has spread and stopped responding to standard hormone therapy. The goal is to find the safest and most …
Matched conditions: MCRPC (METASTATIC CASTRATION-RESISTANT PROSTATE CANCER)
Phase: PHASE1, PHASE2 • Sponsor: Celcuity Inc • Aim: Disease control
Last updated May 26, 2026 03:04 UTC
-
New hope for hard-to-treat prostate cancer: drug-radiation combo enters trial
Disease control Recruiting nowThis study tests whether adding a new drug (SHR-1701) to targeted radiation (SBRT) can slow down advanced prostate cancer that no longer responds to hormone therapy. About 66 men aged 18-80 with metastatic castration-resistant prostate cancer will take part. The main goal is to s…
Matched conditions: MCRPC (METASTATIC CASTRATION-RESISTANT PROSTATE CANCER)
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated May 26, 2026 02:47 UTC
-
New hope for advanced cancer: experimental drug MHB048C enters human trials
Disease control Recruiting nowThis study tests a new drug called MHB048C in people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it can shrink tumors. About 200 adults will take part in this early-phase trial.
Matched conditions: MCRPC (METASTATIC CASTRATION-RESISTANT PROSTATE CANCER)
Phase: PHASE1, PHASE2 • Sponsor: Minghui Pharmaceutical (Hangzhou) Ltd • Aim: Disease control
Last updated May 18, 2026 12:05 UTC
-
New hope for Hard-to-Treat prostate cancer: drug combo trial launches
Disease control Recruiting nowThis study tests whether the drug talazoparib, given alone or with enzalutamide, can slow cancer growth in men with a specific type of advanced prostate cancer (metastatic castration-resistant) that has certain gene mutations (HRR) and has already progressed after treatment with …
Matched conditions: MCRPC (METASTATIC CASTRATION-RESISTANT PROSTATE CANCER)
Phase: PHASE2 • Sponsor: Prostate Cancer Clinical Trials Consortium • Aim: Disease control
Last updated May 18, 2026 12:00 UTC
-
New radioactive drug targets tough prostate cancer in early trial
Disease control Recruiting nowThis early-phase study tests a new radioactive drug called [225Ac]Ac-AKY-2519 in people with a hard-to-treat type of advanced prostate cancer (metastatic castration-resistant prostate cancer). The drug targets a protein (B7-H3) on cancer cells to deliver radiation directly to tum…
Matched conditions: MCRPC (METASTATIC CASTRATION-RESISTANT PROSTATE CANCER)
Phase: PHASE1 • Sponsor: Aktis Oncology, Inc. • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
Targeted radiation zaps Hard-to-Treat cancers in first human trial
Disease control Recruiting nowThis study tests a new drug that delivers radiation directly to cancer cells with a specific marker (GRPR). It is for adults with advanced cancers like prostate, breast, lung, or colon cancer that have come back or spread. The main goal is to find a safe dose and check for side e…
Matched conditions: MCRPC (METASTATIC CASTRATION-RESISTANT PROSTATE CANCER)
Phase: PHASE1 • Sponsor: Orano Med LLC • Aim: Disease control
Last updated May 06, 2026 16:03 UTC
-
New imaging study tracks cancer clones to outsmart drug resistance
Knowledge-focused Recruiting nowThis study uses special PET scans to see how each individual prostate cancer tumor (metastasis) responds to treatment. Researchers will scan 45 men with advanced prostate cancer before, during, and after therapy to find out why some tumors shrink while others grow. The goal is to…
Matched conditions: MCRPC (METASTATIC CASTRATION-RESISTANT PROSTATE CANCER)
Phase: NA • Sponsor: Frederic Pouliot • Aim: Knowledge-focused
Last updated May 22, 2026 14:05 UTC